FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117364326> ?p ?o ?g. }

• W2117364326 endingPage "202" @default.
• W2117364326 startingPage "1" @default.
• W2117364326 abstract "Background Dupuytren’s disease is a slowly progressive condition of the hand, characterised by the formation of nodules in the palm that gradually develop into fibrotic cords. Contracture of the cords produces deformities of the fingers. Surgery is recommended for moderate and severe contractures, but complications and/or recurrences are frequent. Collagenase clostridium histolyticum (CCH) has been developed as a minimally invasive alternative to surgery for some patients. Objectives To assess the clinical effectiveness and cost-effectiveness of collagenase as an alternative to surgery for adults with Dupuytren’s contracture with a palpable cord. Data sources We searched all major electronic databases from 1990 to February 2014. Review methods Randomised controlled trials (RCTs), non-randomised comparative studies and observational studies involving collagenase and/or surgical interventions were considered. Two reviewers independently extracted data and assessed risk of bias of included studies. A de novo Markov model was developed to assess cost-effectiveness of collagenase, percutaneous needle fasciotomy (PNF) and limited fasciectomy (LF). Results were reported as incremental cost per quality-adjusted life-year (QALY) gained. Deterministic and probabilistic sensitivity analyses were undertaken to investigate model and parameter uncertainty. Results Five RCTs comparing collagenase with placebo (493 participants), three RCTs comparing surgical techniques (334 participants), two non-randomised studies comparing collagenase and surgery (105 participants), five non-randomised comparative studies assessing various surgical procedures (3571 participants) and 15 collagenase case series (3154 participants) were included. Meta-analyses of RCTs assessing CCH versus placebo were performed. Joints randomised to collagenase were more likely to achieve clinical success. Collagenase-treated participants experienced significant reduction in contracture and an increased range of motion compared with placebo-treated participants. Participants treated with collagenase also experienced significantly more adverse events, most of which were mild or moderate. Four serious adverse events were observed in the collagenase group: two tendon ruptures, one pulley rupture and one complex regional pain syndrome. Two tendon ruptures were also reported in two collagenase case series. Non-randomised studies comparing collagenase with surgery produced variable results and were at high risk of bias. Serious adverse events across surgery studies were low. Recurrence rates ranged from 0% (at 90 days) to 100% (at 8 years) for collagenase and from 0% (at 2.7 years for fasciectomy) to 85% (at 5 years for PNF) for surgery. The results of the de novo economic analysis show that PNF was the cheapest treatment option, whereas LF generated the greatest QALY gains. Collagenase was more costly and generated fewer QALYs compared with LF. LF was £1199 more costly and generated an additional 0.11 QALYs in comparison with PNF. The incremental cost-effectiveness ratio was £10,871 per QALY gained. Two subgroup analyses were conducted for a population of patients with moderate and severe disease and up to two joints affected. In both subgroup analyses, collagenase remained dominated. Limitations The main limitation of the review was the lack of head-to-head RCTs comparing collagenase with surgery and the limited evidence base for estimating the effects of specific surgical procedures (fasciectomy and PNF). Substantial differences across studies further limited the comparability of available evidence. The economic model was derived from a naive indirect comparison and was hindered by a lack of suitable data. In addition, there was considerable uncertainty about the appropriateness of many assumptions and parameters used in the model. Conclusions Collagenase was significantly better than placebo. There was no evidence that collagenase was clinically better or worse than surgical treatments. LF was the most cost-effective choice to treat moderate to severe contractures, whereas collagenase was not. However, the results of the cost–utility analysis are based on a naive indirect comparison of clinical effectiveness, and a RCT is required to confirm or refute these findings. Study registration This study is registered as PROSPERO CRD42013006248. Funding The National Institute for Health Research Health Technology Assessment programme." @default.
• W2117364326 created "2016-06-24" @default.
• W2117364326 creator A5002556668 @default.
• W2117364326 creator A5005990980 @default.
• W2117364326 creator A5018700194 @default.
• W2117364326 creator A5026201989 @default.
• W2117364326 creator A5030692845 @default.
• W2117364326 creator A5040539473 @default.
• W2117364326 creator A5046292035 @default.
• W2117364326 creator A5070808034 @default.
• W2117364326 creator A5080292819 @default.
• W2117364326 creator A5090393467 @default.
• W2117364326 date "2015-10-01" @default.
• W2117364326 modified "2023-10-10" @default.
• W2117364326 title "Collagenase clostridium histolyticum for the treatment of Dupuytren’s contracture: systematic review and economic evaluation" @default.
• W2117364326 cites W1660053632 @default.
• W2117364326 cites W1791657458 @default.
• W2117364326 cites W1804636981 @default.
• W2117364326 cites W185040227 @default.
• W2117364326 cites W1965436645 @default.
• W2117364326 cites W1969693784 @default.
• W2117364326 cites W1971286645 @default.
• W2117364326 cites W1971403314 @default.
• W2117364326 cites W1972245875 @default.
• W2117364326 cites W1973742103 @default.
• W2117364326 cites W1973811478 @default.
• W2117364326 cites W1973850196 @default.
• W2117364326 cites W1975130410 @default.
• W2117364326 cites W1978552046 @default.
• W2117364326 cites W1980248957 @default.
• W2117364326 cites W1980291416 @default.
• W2117364326 cites W1980916987 @default.
• W2117364326 cites W1996632595 @default.
• W2117364326 cites W1997640920 @default.
• W2117364326 cites W2000021110 @default.
• W2117364326 cites W2000473044 @default.
• W2117364326 cites W2002499552 @default.
• W2117364326 cites W2005278720 @default.
• W2117364326 cites W2006415130 @default.
• W2117364326 cites W2007100546 @default.
• W2117364326 cites W2007439531 @default.
• W2117364326 cites W2010970725 @default.
• W2117364326 cites W2011881883 @default.
• W2117364326 cites W2012219969 @default.
• W2117364326 cites W2012864425 @default.
• W2117364326 cites W2013680360 @default.
• W2117364326 cites W2013897126 @default.
• W2117364326 cites W2015662100 @default.
• W2117364326 cites W2027806688 @default.
• W2117364326 cites W2030750250 @default.
• W2117364326 cites W2034636244 @default.
• W2117364326 cites W2036572244 @default.
• W2117364326 cites W2037324722 @default.
• W2117364326 cites W2042527887 @default.
• W2117364326 cites W2047512479 @default.
• W2117364326 cites W2048641828 @default.
• W2117364326 cites W2048826128 @default.
• W2117364326 cites W2055251975 @default.
• W2117364326 cites W2061243620 @default.
• W2117364326 cites W2061661616 @default.
• W2117364326 cites W2063322965 @default.
• W2117364326 cites W2066436633 @default.
• W2117364326 cites W2067153314 @default.
• W2117364326 cites W2068608716 @default.
• W2117364326 cites W2070349233 @default.
• W2117364326 cites W2073716154 @default.
• W2117364326 cites W2082908125 @default.
• W2117364326 cites W2086283186 @default.
• W2117364326 cites W2089417889 @default.
• W2117364326 cites W2090305710 @default.
• W2117364326 cites W2091030062 @default.
• W2117364326 cites W2092299889 @default.
• W2117364326 cites W2093631232 @default.
• W2117364326 cites W2102303498 @default.
• W2117364326 cites W2110104001 @default.
• W2117364326 cites W2110544670 @default.
• W2117364326 cites W2112403469 @default.
• W2117364326 cites W2114488753 @default.
• W2117364326 cites W2114995016 @default.
• W2117364326 cites W2115229446 @default.
• W2117364326 cites W2115345891 @default.
• W2117364326 cites W2119360891 @default.
• W2117364326 cites W2131607920 @default.
• W2117364326 cites W2136472564 @default.
• W2117364326 cites W2137042180 @default.
• W2117364326 cites W2137099734 @default.
• W2117364326 cites W2139210909 @default.
• W2117364326 cites W2146583529 @default.
• W2117364326 cites W2148676110 @default.
• W2117364326 cites W2156943337 @default.
• W2117364326 cites W2166884592 @default.
• W2117364326 cites W2168467581 @default.
• W2117364326 cites W2257827995 @default.
• W2117364326 cites W2267198945 @default.
• W2117364326 cites W2326560962 @default.
• W2117364326 cites W2339613213 @default.
• W2117364326 cites W2354959122 @default.
• W2117364326 cites W2398201441 @default.

• next